Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06895486Phase 2Recruiting

Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation

Role: collaborator

NCT07204171Phase 1Not Yet Recruiting

Phase 1 Study of Oral MG001

Role: collaborator

NCT06799013Phase 1Recruiting

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever

Role: collaborator

NCT05654467Phase 2Recruiting

Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama

Role: collaborator

All 4 trials loaded